Pfizer Acquires Amplyx to Expand its Infectious Disease Portfolio

 Pfizer Acquires Amplyx to Expand its Infectious Disease Portfolio

Pfizer Acquires Amplyx to Expand its Infectious Disease Portfolio

Shots:

  • The acquisition expands the anti-infectives pipeline with the addition of Amplyx’s P-II candidate, Fosmanogepix (APX001) which is being evaluated in both IV and oral formulations for the treatment of patients with invasive fungal infections
  • Pfizer also retains ownership of the Amplyx early-stage pipeline, including antiviral (MAU868) and antifungal (APX2039) therapies. The acquisition follows an initial equity investment by Pfizer in December 2019 as part of Amplyx’s Series C funding
  • Fosmanogepix has demonstrated broad-spectrum activity in-vitro and showed wide distribution to various tissues, including brain, lung, kidney, and eye

Click here to­ read full press release/ article | Ref: Pfizer | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post